Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
We propose a methodology for conducting phase II clinical trials in settings where the disease is categorized into multiple subtypes. A hierarchical Bayesian model is assumed for treatment effects within the subtypes. The hierarchical model, which is tailored to each particular application, allows treatment effects to differ across subtypes while assuming a priori that the effects are exchangeable and correlated. Two applications are described. The first is a trial of imatinib for sarcoma in which treatment activity is characterized by a binary indicator of tumour response. The second is a phase II trial of a new preparative regimen for allogeneic bone marrow transplantation in patients with haematologic malignancies, with treatment effect characterized by the mean time from transplant to disease progression or death. The applications illustrate how the hierarchical Bayesian model borrows strength across subtypes.
Thall
Peter F
PF
Department of Biostatistics, Box 447, University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030-4095, USA. rex@manderson.org
Wathen
J Kyle
JK
Bekele
B Nebiyou
BN
Champlin
Richard E
RE
Baker
Laurence H
LH
Benjamin
Robert S
RS
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001499:Bayes Theorem; D001549:Benzamides; D016026:Bone Marrow Transplantation / Q000379:methods; D002066:Busulfan / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D018450:Disease Progression; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D009190:Myelodysplastic Syndromes / Q000628:therapy; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012107:Research Design; D012509:Sarcoma / Q000188:drug therapy; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine